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Abstract
Opportunistic and other infections have declined since the introduction of highly active antiretroviral therapy
(HAART) in developed countries but few studies have addressed the impact of HAART in HIV-infected children
from developing countries. This study examines the prevalence and incidence of opportunistic and other in-
fections in Latin America during the HAART era. Vertically HIV-infected children enrolled in a cohort study
between 2002 and 2007 were followed for the occurrence of 29 targeted infections. Cross-sectional and longi-
tudinal analyses were performed to calculate the prevalence of infections before enrollment and the incidence
rates of opportunistic and other infections after enrollment. Comparisons were made with data from a U.S.
cohort (PACTG 219C). Of the 731 vertically HIV-infected children 568 (78%) had at least one opportunistic or
other infection prior to enrollment. The most prevalent infections were bacterial pneumonia, oral candidiasis,
varicella, tuberculosis, herpes zoster, and Pneumocystis jiroveci pneumonia. After enrollment, the overall inci-
dence was 23.5 per 100 person-years; the most common infections (per 100 person-years) were bacterial pneu-
monia (7.8), varicella (3.0), dermatophyte infections (2.9), herpes simplex (2.5), and herpes zoster (1.8). All of
these incidence rates were higher than those reported in PACTG 219C. The types and relative distribution of
infections among HIV-infected children in Latin America in this study are similar to those seen in the United
States but the incidence rates are higher. Further research is necessary to determine the reasons for these higher
rates.
Introduction
The introduction of highly active antiretroviral therapy(HAART) has led to HIV becoming a chronic illness with
a reduced incidence of opportunistic and other infections and
significantly reduced mortality among HIV-infected chil-
dren.1,2 In the 219C study of the Pediatric AIDS Clinical Trials
Group (PACTG) in the United States the incidence of 29 tar-
geted opportunistic and other infections in the HAART era
was uncommon compared to the pre-HAART era.3 Another
U.S.-based study, the Perinatal AIDS Collaborative Trans-
mission Study, found an 86–100% reduction in opportunistic
infections in the HAART era, with rates similar to those re-
ported from the 219C study.4 Not surprisingly, both of these
U.S.-based studies found an increased risk of opportunistic
infections among those with lower CD4 counts.3,4 However,
data from an Italian pediatric HIV registry demonstrated that
severe bacterial infections, particularly pneumonia, still oc-
curred at high rates even in the absence of severe CD4 cell
depletion.5
Few studies have prospectively analyzed the incidence of
opportunistic and other infections in HIV-infected children
from Latin America during theHAART era. Studies in Brazil,6
Chile,7 Mexico,8 and Honduras9 have examined specific op-
portunistic illnesses, such as cytomegalovirus (CMV) infec-
tions, or overall incidence of opportunistic illnesses, but none
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2Westat, Rockville, Maryland.
3Hospital dos Servidores do Estado, Rio de Janeiro, Brazil.
4Universidade de Sa˜o Paulo at Ribeira˜o Preto, Brazil.
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was prospectively performed across a range of sites in the
HAART era. This work represents the first regional analysis of
opportunistic and other infections among HIV-infected chil-
dren in Latin America and the Caribbean in the HAART era.
We also compare the frequency of first occurrence of specific
infectious illnesses in Latin America and the Caribbean to the
occurrence of these illnesses in the United States as reported in
the PACTG 219C cohort.3
Materials and Methods
The Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NICHD) International Site
Development Initiative (NISDI) pediatric protocol is a pro-
spective cohort study following HIV-infected children at
multiple clinical sites in Latin America. A description of this
protocol and the cohort has been published.10 When enroll-
ment began in the autumn of 2002, HIV-infected infants,
children, and adolescents (£ 21 years of age) who were re-
ceiving care at the participating sites (11 in Brazil and 2 each in
Mexico and Argentina) were eligible; in 2006 one site each in
Peru and Jamaica was added. The protocol was approved by
the ethical review boards of each clinical site, by the spon-
soring institution (NICHD), the data management and sta-
tistical center (Westat), and the Brazilian National Ethics
Committee (CONEP). Informed consent was obtained from
adult participants or either parents or guardians of minor
participants.
Eligibility for this analysis was limited to vertically infected
participants in the NISDI pediatric study. The following data
were collected in a standardized fashion during scheduled
study visits twice a year: medical history, physical examina-
tion, and laboratory evaluations (including flow cytometry
and HIV viral load). Height and weight for age11 and HIV
disease classification12 were determined according to defini-
tions of the CDC. Criteria used for the diagnoses of specific
diseases were those developed for NISDI but based upon the
criteria used by the PACTG.3 Infections with a documented
causative agent were classified as ‘‘proven’’; those without
documentation were designated ‘‘presumed.’’ We targeted 29
infections classified as infectious events B or C in the CDC
HIV disease classification system as well as other infections
analyzed in the PACTG 219C study in order to provide
comparisons. At enrollment into NISDI, information was
collected retrospectively regarding all antiretroviral (ARV)
regimens since initiation of therapy; additional information
regarding ARVs were also collected at each study visit.
HAART was defined as any protease inhibitor (PI) and/or
nonnucleoside reverse transcriptase inhibitor (NNRTI) ther-
apy. Those not on a PI and/or NNRTI but on some other ARV
were classified as other ARV.
Statistical methods
The proportion of children with each of the 29 targeted
infections prior to enrollment to the NISDI protocols was
calculated based upon retrospective information. Incidence
rates (IRs) for the first opportunistic or other infection and
95% confidence intervals (CI) were calculated per 100 person-
years under a Poisson distribution for the entire study pop-
ulation during participation on the study; IRs and 95% CI
were also calculated for the first occurrence of each of the 29
targeted infections. Person-years of follow-upwere calculated
from study entry until the first infection or until the end of
study participation (withdrawal from the study, death, or
end of study); however, a child with a first infection could
continue to contribute person-time for different subsequent
infections. For analysis purposes, laboratory assays, particu-
larly CD4% and viral load, were those measured at the visit
immediately prior to the first occurrence of an opportunistic
or other infection. For the description of these numerical
variables, we also calculated the median and quartile range
(QR). Age was calculated at the time of the infection. All an-
alyses were conducted using the SAS statistical software
version 9.0 (SAS Institute Inc., Cary, NC). Incidence rates
obtained from NISDI were compared to rates obtained in
PACTG 219C3 using the approximate interval estimationwith
follow-up data by Rothman.13
Results
Characteristics of the study population
Between September 2002 and October 2007, 731 vertically
HIV-infected children enrolled in NISDI. As shown in Table 1,
66%were born in Brazil, 56%were girls, 43%were < 5 years of
age, and 67% were on HAART. These 731 children were on
study for a median of 3.9 years (QR 3.3–4.3 years) and con-
tributed 1633 person-years of follow-up to the first infection or
end of study for those without infections. Forty-six (6.3%)
were lost to follow-up: the sites were unable to locate 17 of the
children, 13 moved out of the area, 13 died during follow-up,
and 3 withdrew consent.
Prevalence of opportunistic and other infections
prior to study entry
Overall, there were 1436 infections reported among 568
(78%) children prior to enrolling in NISDI with 26 of the 29
infections investigated being identified. Bacterial pneumonia
was the most common infection for children of all ages. For
children older than 1 year of age the most common infections
were bacterial pneumonia, varicella, dermatophyte infections,
and herpes simplex infections. There were no reports of in-
vasive fungal infections, nontuberculous mycobacterial dis-
ease, or bacterial septic arthritis. Table 2 shows the prevalence
of the targeted infections compared to those reported in
PACTG 219C.3 Among the seven most common infections
seen in theNISDI cohort all except oral candidiasis and herpes
zoster were reported at a greater frequency in NISDI, with
95% confidence intervals that did not overlap with those
reported from the PACTG cohort. In addition, bacterial ab-
scesses, urinary tract infections, lymphadenitis, herpes sim-
plex, and bacterial meningitis were more prevalent in the
NISDI cohort. Only two conditions, dermatophyte infections
and lymphoid interstitial pneumonitis, were reported more
frequently in the PACTG cohort than in the NISDI cohort.
Incidence of first opportunistic or other infection
during the study period
Overall, 383 (52.4%) of the children experienced at least one
of the targeted infections during study follow-up. Themedian
age at the first infection was 6 years. Table 1 summarizes the
other clinical features for these 383 children prior to their first
diagnosed infection. The CD4% was ‡ 25% in 57% and the
viral load was < 10,000 copies/ml in 49% of the children who
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experienced one of these targeted infections. Forty-nine per-
cent of the study population had received at least one dose of
pneumococcal vaccination and 22% had received at least one
dose of varicella vaccination by the time of enrollment.
In total, there were 637 incident infections among these 383
children after enrollment attributed to 26 of the 29 infections
investigated. There were no reports of invasive fungal infec-
tions, bacterial osteomyelitis, or measles. Table 3 summarizes
the IRs for each of the targeted infections and presents the
comparison between the NISDI cohort and the PACTG 219C
cohort. After enrollment, the overall incidence was 23.5 per
100 person-years with the most common infections being
bacterial pneumonia, varicella, dermatophyte infections,
herpes simplex virus, and herpes zoster. Although similar to
the PACTG 219C cohort, in which bacterial pneumonia, her-
pes zoster, oral candidiasis, dermatophyte infections, and
varicella were the fivemost common infections, our study had
significantly higher IRs. Likewise, other infections that were
more prevalent prior to enrollment, lymphadenitis, urinary
tract infections, and proven diarrhea, also had higher IRs than
those seen in the PACTG cohort.
Most cases of diarrhea reported fromNISDIwere not tested
for an etiologic agent, hence were not included in our analy-
ses. If these presumed infectious diarrheas had been included,
the IR (6.3 per 100 person-years) would have made this the
second most common infection in the NISDI cohort.
No statistical difference was found in CD4% or VL levels
between those on HAART and those not on HAART prior to
their first infection; thus we present the age, CD4%, and viral
load prior to each of these targeted infections without regard
to treatment regimen (Table 4). Bacterial pneumonia, was the
most common infection for children of all ages. For children
older than 1 year of age the most common infections where
bacterial pneumonia, varicella, dermatophyte infections, and
herpes simplex infections.
Fifty percent or greater of the following CDC class C
conditions––bacterial meningitis, cytomegalovirus not reti-
nitis, CNS toxoplasmosis, and Cryptosporidium infections—
occurred among children whose CD4% was 25% or higher;
the majority of bacterial pneumonia, Pneumocystis jiroveci,
sepsis, and tuberculosis occurred among childrenwith CD4%
< 25%. All cases of esophageal candidiasis (2), nontuberculous
mycobacterial disease (2), and progressive multifocal leu-
koencephalopathy (2) occurred in children with CD4% less
than 15% (data not shown). As we have reported before,
during follow-up, 13 patients died, all but two of an infec-
tious cause.10
Among the 383 children who had one of the targeted in-
fections, 200 (52.2%) had two or more episodes during the
study period. Of the 170 children who had bacterial pneu-
monia 58 (34.1%) had at least two episodes (29 had two epi-
sodes, 12 had three episodes, and 17 had four or more
episodes). Of the 60 children who had herpes simplex infec-
tions 12 (20%) had at least two episodes (seven had two epi-
sodes, three had three episodes, and two had four episodes)
(data not shown).
Discussion
In this prospective observational study of vertically HIV-
infected children in Latin America we have shown that the
relative distribution of 29 targeted infections seen during the
Table 1. Characteristics of Vertically HIV-Infected
Children at Enrollment and at the First
Opportunistic Infection After Enrollment on NISDI
Study variable
At enrollment
N = 731 (%)
Experiencing an
OI on study
N = 383 (%)
Country of birth
Brazil 483 (66.1) 285 (74.4)
Mexico 118 (16.1) 45 (11.8)
Argentina 71 (9.7) 22 (5.7)
Peru 37 (5.1) 20 (5.2)
Jamaica 22 (3.0) 11 (2.9)
Gender
Male 325 (44.5) 174 (45.4)
Female 406 (55.5) 209 (54.6)
Age (years)
Median (QR) 5.0 (3.0–9.0) 6.0 (4.0–10.0)
< 1 37 (5.1) 11 (2.9)
1-4 275 (37.6) 113 (29.5)
5-9 280 (38.3) 160 (41.8)
‡ 10 139 (19.0) 99 (25.8)
HIV classification (CDC)
N 101 (14.0) 39 (10.3)
A 155 (12.5) 76 (20.1)
B 233 (32.3) 128 (33.9)
C 233 (32.3) 135 (35.7)
Missinga 9 5
ARV regimen
PI + NNRTI HAART 55 (7.5) 14 (3.6)
PI HAART 328 (44.9) 186 (48.6)
NNRTI HAART 103 (14.1) 63 (16.4)
Other ARV 127 (17.4) 75 (19.6)
No ARV 118 (16.1) 45 (11.8)
CD4 percent
Median (QR) 27% (21–34) 26% (19–34)
< 15% 74 (11.5) 49 (14.1)
15–24% 187 (29.0) 102 (29.4)
‡ 25% 384 (59.5) 196 (56.5)
Missinga 86 36
HIV viral load (copies/ml)
Median (QR) 7.9K (0.2–44.3K) 10.5K (0.7–63K)
< 1000 225 (31.0) 100 (26.5)
1000– < 10,000 156 (21.5) 84 ( 22.2)
‡ 10,000 345 (47.5) 194 (51.3)
Missinga 5 5
Weight/age (CDC z-score)
£ 2SD from the mean 118 (16.2) 60 (15.8)
– 2 SD from the mean 601 (82.4) 318 (83.7)
> 2SD above the mean 10 (1.4) 2 (0.5)
Missinga 2 3
Height/age (CDC z-score)
£ 2 SD from the mean 148 (20.4) 74 (19.5)
– 2 SD from the mean 574 (79.2) 304 (80.2)
> 2 SD above the mean 3 (0.4) 1 (0.3)
Missinga 6 4
BMI percentile
< 5th percentile 68 (9.4) 42 (11.2)
5th < 95th percentile 615 (84.8) 321 (85.4)
‡ 95th percentile 42 (5.8) 13 (3.4)
Missinga 6 7
aMissing values are not included in percentages.
QR, quartile range represents the 25th and 75th quartile for the
population; SD, standard deviation; OI, opportunistic infection;
ARV, antiretroviral; PI, protease inhibitor; HAART, highly active
antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase
inhibitor; BMI, body mass index.
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Table 2. Proportion of HIV-Infected Children Reporting Opportunistic and Other Infections
Prior to Enrollment in NISDI and PACTG
NISDIa PACTG 219C3
Category N = 731 Percent (95% CI)b N= 2767 Percent (95% CI)b
Overall first infections 568 77.7 (74.7–80.7) Not reported
Bacterial pneumonia 384 52.5 (48.9–56.2) 698 25.2 (23.6–26.8)
Oral candidiasis 212 29.0 (25.7–32.3) 761 27.5 (25.8–29.2)
Varicella 161 22.0 (19.0–25.0) 395 14.3 (13.0–15.6)
Tuberculosis 65 8.9 (6.8–11.0) 17 0.6 (0.3–0.9)
Herpes zoster 63 8.6 (6.6–10.6) 280 10.0 (9.0–11.2)
Pneumocystis jiroveci 61 8.3 (6.3–10.3) 79 2.9 (2.2–3.5)
Diarrhea, proven 56 7.7 (5.7–9.6) 104 3.8 (3.1–4.5)
Molluscum contagiosum 56 7.7 (5.7–9.6) 151 5.5 (4.6–6.3)
Abscess, bacterial 48 6.6 (4.8–8.4) 5 0.2 (0.0–0.3)
Bacteremia/septicemia 48 6.6 (4.8–8.4) 220 8.0 (6.9–9.0)
Dermatophyte infections 46 6.3 (4.5–8.1) 422 15.3 (13.9–16.6)
Urinary tract infections 44 6.0 (4.3–7.7) 68 2.5 (1.9–3.0)
Lymphadenitis 40 5.5 (3.8–7.1) 11 0.4 (0.2–0.6)
Lymphoid interstitial pneumonitis 39 5.3 (3.7–7.0) 325 11.8 (10.6–13.0)
Herpes simplex 27 3.7 (2.3–5.1) 24 0.9 (0.5–1.2)
Bacterial meningitis 23 3.1 (1.9–4.4) 13 0.5 (0.2–0.7)
Viral hepatitis 15 2.1 (1.0–3.1) 60 2.2 (1.6–2.7)
Cytomegalovirus not retinitis 11 1.5 (0.6–2.4) 49 1.8 (1.3–2.3)
Esophageal/pulmonary candidiasis 10 1.4 (0.5–2.2) 39 1.4 (1.0–1.9)
Toxoplasmosis (CNS) 9 1.2 (0.4–2.0) 5 0.2 (0.0–0.3)
Cytomegalovirus retinitis 6 0.8 (0.2–1.5) 10 0.4 (0.1–0.6)
Measles 5 0.7 (0.1–1.3) 5 0.2 (0.0–0.3)
aNISDI also reported three cases of progressive multifocal leukoencephalopathy, two cases of bacterial osteomyelitis, and one each of
Cryptosporidium and encephalitis.
bHigher reporting of specific infections between cohorts shown by bolded nonoverlapping intervals.
Table 3. Overall Incidence Rates of First-Time Infections for Categories with Four or More First
Events Among Patients Enrolled in NISDI Compared with PACTG 219C
NISDIa PACTG 219C3
Category
Incident
events
Person
Years
IR of events/100
person years (95% CI)
Incident
events
Person
Years
IR of events/100
person years (95% CI) pb
Overall first infectionsc 383 1633 23.45 (21.10–25.80) — — —
Bacterial pneumonia 170 2174 7.82 (6.64–8.99) 123 5726 2.15 (1.79–2.56) <0.001
Varicella 71 2385 2.98 (2.28–3.67) 29 6623 0.44 (0.29–0.63) <0.001
Dermatophyte infections 69 2409 2.86 (2.19–3.54) 57 6483 0.88 (0.67–1.14) <0.001
Herpes simplex virus 60 2440 2.46 (1.84–3.08) 11 7807 0.14 (0.07–0.25) <0.001
Herpes zoster 45 2460 1.83 (1.29–2.36) 77 6925 1.11 (0.88–1.39) 0.02
Abscess, bacterialc 37 2448 1.51 (1.02–2.00) — — —
Oral candidiasis 36 2466 1.46 (0.98–1.94) 52 5576 0.93 (0.70–1.22) 0.06
Molluscum contagiosum 31 2461 1.26 (0.82–1.70) 23 7392 0.31 (0.20–0.47) <0.001
Lymphadenitis 22 2495 0.88 (0.51–1.25) 7 7849 0.09 (0.04–0.18) <0.001
Urinary tract infection 19 2509 0.76 (0.42–1.10) 27 7660 0.35 (0.23–0.51) 0.03
Infectious diarrhea 18 2497 0.72 (0.39–1.05) 9 7552 0.12 (0.05–0.23) <0.001
P. jiroveci pneumonia 9 2526 0.36 (0.12–0.59) 7 7668 0.09 (0.04–0.19) 0.03
Lymphoid interstitial
pneumonitis
7 2533 0.28 (0.07–0.48) 6 6889 0.09 (0.03–0.19) 0.09
Bacterial meningitisc 7 2522 0.28 (0.07–0.48) — — —
Tuberculosis (TB) 7 2523 0.28 (0.07–0.48) < 4 — —
Viral hepatitis 6 2525 0.24 (0.05–0.43) 11 7729 0.14 (0.07–0.25) 0.37
Bacteremia/septicemia 5 2529 0.20 (0.02–0.37) 25 7192 0.35 (0.22–0.51) 0.18
CMV not retinitisc 4 2534 0.16 (0.0–0.31) — — —
aNISDI reported < 4 events for toxoplasmosis (3), non-TB mycobacteria (2), esophageal or pulmonary candidiasis (2), Cryptosporidium (2)c,
progressive multifocal leukoencephalopathy (2)c, CMV retinitis (1), encephalitis (1)c, septic arthritis, bacterial (1)c.
bFisher’s exact test.
cNot reported in PACTG 219C.3
IR, incidence rate; CMV, cytomegalovirus.
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HAART era is similar to results from the United States but
that the prevalence and IRs are generally higher. Because this
study did not begin until 2002, no attempt was made to
compare rates in those on HAART versus those not on
HAART since all participants could realistically be considered
to be treated in the HAART era. However, we were able to
compare the NISDI experience in Latin America with the 2767
HIV-infected children enrolled in the U.S. PACTG cohort.3
The characteristics of the PACTG cohort were similar to
NISDI in the enrollment time frame (September 2000 to De-
cember 2004), median length of follow-up (3.4 years), median
CD4% (30), and the percentage on HAART (69%), but with a
lower median viral load (1208 copies/ml) and older median
age at enrollment (9.9 years). The IR of any first infection in
our study was 23.5 per 100 person-years, and the most com-
mon incident infections (bacterial pneumonia, varicella, der-
matophyte infections, herpes simplex, and herpes zoster)
were more common than in the 219C cohort.3
The IR of bacterial pneumonia was higher than has been
reported in the 219C study and other studies in the United
States and Europe,3,5 and was similar to the rate seen in the
pre-HAART era in Spain14 and the rate seen after 12months of
HAART in Zambian children.15 While this should prompt
further study, one explanation may well be the difficulty in
diagnosing bacterial pneumonia and tuberculosis, especially
in children, and the chance that episodes of nonbacterial re-
spiratory illness or tuberculosis were recorded as bacterial.16
Nevertheless, it is striking that 43% of children with an inci-
dent episode of bacterial pneumonia had a CD4% ‡ 25. This
high rate of bacterial pneumonia despite adequate CD4 count
has also been seen in the studies in other settings and offers
evidence of continued immunologic deficits in the face of ef-
fective antiretroviral therapy in children.3,5,15
The rate of herpes zoster in our study was higher than the
rate reported in the 219C study3 but was within the range
reported in a more detailed examination of herpes zoster
among a subset in the 219C study.17 Interestingly, though,
Hispanic ethnicity was associated with higher rates of herpes
zoster in another U.S.-based study of HIV-infected children,
which may be relevant to the Latin American population that
we studied.18 The higher rate of varicella that we saw may be
related to limited use of varicella vaccine in these countries.
In addition to bacterial pneumonia, herpes zoster, varicella,
and Pneumocystis jiroveci pneumonia, the IRs for the following
were also significantly higher in our study compared to re-
sults in the 219C study: dermatophyte infections, herpes
simplex, molluscum contagiosum, lymphadenitis, urinary
tract infections, and infectious diarrhea. The differences be-
tween the results for herpes simplex may be related to a much
more stringent definition in the 219C study, which counted
only episodes refractory to treatment for over 30 days,
whereas we include all reported herpes simplex infections.
The incidence of several infections was not reported in the
219C report due to very few events. For example, the 219C
reported only that there were less than four cases of tuber-
culosis episodes precluding formal statistical comparison
with our NISDI cohort. If we assume there were as many as
three tuberculosis cases, the rate would have been 0.04 to
0.05/100 person-years, making tuberculosis substantially
more common in the NISDI cohort. The IR for only one tar-
geted infection reported from 219C, sepsis or bacteremia, was
higher, but not significantly different than the IR in our study.
The major strengths of this study are the systematic col-
lection of data over a 5-year period with frequent follow-up
(every 6 months) that allowed the capture of events between
visits. In addition, we used essentially the same classification
Table 4. Age, CD4%, and Human Immunodeficiency Virus RNA Prior to First-Time Infections
for Diagnostic Categories with Four or More First Events Among Children Participating
in the NISDI Pediatric Protocol in Latin America and the Caribbean
Age CD4% priora Viral loadb
Number
of children < 1 1–4 5–9 ‡ 10
IQR
(years) < 15%
15–
24% ‡ 25%
IQR
(%) < 1K
1K
< 10K ‡ 10K
IQR
(K)
All first infections 383 11 113 160 99 4–10 49 102 196 19–34 100 84 194 0.7–63
Bacterial pneumonia 170 5 61 70 34 4–9 24 57 73 18–33 35 34 99 3–93
Varicella 71 0 24 37 10 4–8 6 21 37 21–35 24 15 32 0–44
Dermatophyte 69 0 11 31 27 6–11 3 17 43 23–35 25 17 27 0–36
Herpes simplex 60 2 6 29 23 7–11 11 15 30 18–32 16 15 28 0–61
Herpes zoster 45 0 7 17 21 7–12 15 15 14 14–26 6 8 29 2–84
Bacterial abscess 37 0 9 18 10 5–11 3 12 18 22–33 8 12 15 1–36
Oral candidiasis 36 3 14 11 8 3–9 14 10 8 8–25 5 5 26 9–371
Molluscum 31 0 10 15 5 5–9 1 7 21 23–35 5 5 21 3–99
Lymphadenitis 22 0 4 11 7 6–12 2 7 11 16–34 5 2 14 1–62
Urinary tract infections 19 0 6 7 6 3–11 2 4 10 19–32 5 3 11 0–110
Diarrhea, proven 18 2 8 6 2 2–7 5 4 9 14–37 3 4 11 3–196
Pneumocystis jiroveci 9 1 6 1 1 2–19 3 2 4 10–32 0 1 7 38–324
Bacterial meningitis 7 1 1 3 2 3–10 1 2 4 22–40 2 0 4 0–125
LIP 7 1 3 1 2 2–13 0 2 4 17–32 1 1 5 3–182
Tuberculosis 7 1 2 0 4 2–15 2 2 3 13–28 2 4 1 0–9
Viral hepatitis 6 0 1 3 2 8–12 2 2 2 14–31 2 2 2 1–128
Bacteremia septicemia 5 2 1 2 0 0–5 1 2 2 16–25 0 0 4 82–3857
aCD4% (87 missing values).
bViral load < 400 reported as zero (16 missing values).
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system as was used in the 219C cohort study,3 which facili-
tated the comparisons across the two cohorts. Some limita-
tions of the study are fewer participants (compared to PACTG
219C) and low rates of rare diseases (for example, CMV reti-
nitis) leading to unstable IRs for some infections reported in
NISDI. Also, we relied on reported diagnoses and limited
attempts were made to verify the etiologies or confirm the
reports.
In conclusion, although the types and relative distribution
of infections among HIV-infected children in our Latin
American cohort during the HAART era are similar to what
has been seen in the United States, the prevalence and inci-
dence rates are higher. Thus, despite access to HAART, there
is higher morbidity related to infections among HIV-infected
children in Latin America and the Caribbean than in the
United States. This may be due, in part, to the higher preva-
lence of some infections in Latin America (such as diarrhea
and tuberculosis), poorer nutritional status of children, so-
cioeconomic factors, health care quality, and other factors.
Further research is necessary to determine whether these
factors or others are the reasons for these differences in order
to identify improved preventive strategies for HIV-infected
children living in Latin America and in other countries out-
side the United States and Europe.
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